WebCERC-007 (formerly AEVI-007), a fully-human, anti-IL-18 monoclonal antibody for auto-inflammatory diseases, including Adult Onset Still’s Disease (AOSD) and Multiple … WebAevi Genomic Medicine will exclusively license the composition of matter patents, and the Company expects to establish new biological product exclusivity for 12 years from the date of FDA approval of the antibody in the U.S., and at least 10 years from the date of first authorization in Europe. About Aevi Genomic Medicine, Inc.
Aevi Genomic Medicine Provides Top-line Results from the …
WebApr 12, 2024 · Aevi Genomic Medicine, Inc. today announced that results identifying a genomic subset of responders from the SAGA trial of AEVI-001 will be presented at the 6th World Congress on ADHD taking place ... WebDec 13, 2024 · On December 5, 2024, Cerecor, Inc. (NASDAQ:CERC) announced the acquisition of Aevi Genomic Medicine (GNMX) in an all-stock transaction valued at approximately $16.1 million plus contingent value... clean cedar fence
Cerecor to Acquire Aevi Genomic Medicine - Avalo Therapeutics, Inc
WebApr 21, 2024 · Aevi, which was formerly Medgenics, inked a $5 million dealwith CHOP in 2014 to gain exclusive access to the genomic discoveries that come out of the Center for Applied Genomics biobank for the development of drug and diagnostic targets. WebAug 14, 2024 · Aevi Genomic Medicine is developing AEVI-001 as a potential treatment for a sub-population of Attention Deficit Hyperactivity Disorder (ADHD) patients with genetic mutations that disrupt the mGluR ... Web2 days ago · Diem, a former AstraZeneca executive, joined the company as chief business officer in 2024. He was previously at two other local life sciences companies: Amicus Therapeutics and Aevi Genomic Medicine. downtown 2 ql3.1